The Adempas Enrollment Journey A guide to Adempas access information

INDICATIONS

- Adempas (riociguat) tablets is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
- Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class, and to delay clinical worsening.*
- Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominantly patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).
- *Time to clinical worsening was a combined endpoint defined as death (all-cause mortality), heart/lung transplantation, atrial septostomy, hospitalization due to persistent worsening of pulmonary hypertension, start of new PAH-specific treatment, persistent decrease in 6MWD, and persistent worsening of WHO functional class.

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY

Do not administer Adempas (riociguat) tablets to a pregnant female because it may cause fetal harm.

Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and one month after stopping treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment.

For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.

Please see additional Important Safety Information, including Boxed Warning, throughout, and <u>click here</u> for full Prescribing Information.



Enrollment process

All Sections

All sections filled out in blue in the sample form shown on the right must be completed before submitting.

Section 2

Initiation Setting Check the box if the patient is starting Adempas in a hospital setting. Insurance Information

Does your patient have <u>prescription</u> insurance? Medical and prescriptions may be two separate cards.

Diagnosis

Select the most appropriate ICD-10-CM for the patient

- For PAH: choose newly or previously diagnosed
- For CTEPH: choose inoperable or persistent/recurrent

ICD-10-CM codes* are relevant to coding for CTEPH and PAH diagnosis

Coding and classifying the patient's diagnosis and condition are important to support the medical necessity for patients taking Adempas

PAH (WHO Group 1)					
ICD-10-CM Code	Code Description				
I27.0	Primary pulmonary arterial hypertension				
I27.21	Secondary arterial pulmonary hypertension				
	CTEPH (WHO Group 4)				
ICD-10-CM Code	Code Description				
I27.24	Chronic thromboembolic pulmonary hypertension				
This list is for coding p	urposes only and not a complete list of ICD-10-CM				

*This list is for coding purposes only and not a complete list of ICD-10-CN codes. This list does not suggest approval uses or indications.

Adempas® (riociguat) Prescription and Patient Support Program Enrollment Form

Complete this form which is available at <u>www.adempas-us.com</u>. Prescribers and all female patients must be enrolled in the Adempas REMS Program prior to initiating treatment. Please visit <u>www.AdempasREMS.com</u> to access the Adempas REMS materials including the Adempas REMS Patient Enrollment and Consent Form, and fax them along with patient insurance information to the Adempas Program at 1-855-662-5200 or send electronically by visiting <u>www.adempasREMS.com</u>.

SECTION 1 Contact Information


Patient First Name*: Jane		tient st Name*: Smith		Birthdate* (MM/DD/Y	12/01/19 YYY):	Gender*:
Address*: 1 Bayer Drive	City*: Whippan	∿y State*:		Preferred Phone*: 555-5		OK to leave detailed message? □Yes □N
Email: jane.smith@email.com			d Language: lish Spanish	Other (specify)		
Alternate Contact Name:		ernate ntact Phone:		Relationsh to Patient:		
Prescriber Contact Information (*	ndicates required	field)				
Prescriber First Name*: Robert		escriber st Name*: Jowes			NPI*	: 1000000000000000
Address Line 1*: 1800 Orleans Street		dress e 2:	City	Baltímore	State:	Zip Code:
Office Contact: Jennifer Anderson	Pho	one: 222-333-44	4.4	Fax:	-444-5555	21287

SECTION **2** Patient Information

Patient Information (* indicates required field)	
Is Patient starting Adempas in a hospital setting? Yes Vo Start Date:	Discharge Date:
Does the patient have prescription coverage*? Ves No	
Patient's local pharmacy:	Phone:
*PROVIDE ALL PATIENT INSURANCE INFORMATION, INCLUDING DI	RUG BENEFITS (FRONT AND BACK OF CARD) WITH THIS FORM.
Please check one ICD-10 Code*:	Therapy Status:
Pulmonary arterial hypertension Chronic thromboembolic pulmonary hyperten	nsion OTHER (please specify) Initial therapy (monotherapy or in combination Add-on therapy
✓ 127.0 127.24 127.21 Inoperable	Transition from other therapy
Persistent/Recurrent	

Prescriber will comply with all Surescripts' terms and conditions including confidentiality, commercial messaging, privacy and security, applicable laws, and use of data. All Surescripts disclaimers apply. A full list of terms and conditions is available at https://ubc.com/surescriptsterms/

SECTION 3 Prescription



Section 3

Prescription Starting Dose and Titration Schedule

Starting dose can be selected with # of refills
Titration schedule can be selected with # of refills

In addition to the Adempas Prescription and Enrollment Form, some states may require a second prescription to be sent directly to the specialty pharmacy (Accredo or Caremark).

Prescription Healthcare Nurse Interactions

- In partnership with your patient, you will discuss if your patient will decide to choose to have follow-up healthcare nurse interactions, which is part of the patient support program. Physicians cannot request nursing services
- As a result, the prescriber will select one of two options in this section
- NOTE: If the option for healthcare nurse interactions is selected in Section 3, it must also be selected in Section 4.
 See below

Prescribers are required to sign and date this section.

3 simple ways to enroll

- 1. Electronically with e-signature at AdempasHCP.com
- 2. Email: AdempasSupport@ubc.com
- 3. Fax: 1-855-662-5200

Aim Patient



Please see additional Important Safety Information, including Boxed Warning, throughout, and <u>click here</u> for full Prescribing Information. REMS Enrollment Form

Adempas Enrollment Form

PA and Appeals Process

Aim Patient Support Program

Enrollment process (continued)

To prescribe Adempas, the following forms must be completed and submitted with signatures:

- Adempas Prescription and Patient Support Program Enrollment Form Only the prescription portion of this form is required to be completed in order to initiate and fulfill a prescription. The Patient Support Enrollment section is optional and allows patients to register for some or all of the patient support program
 - THE PHYSICIAN CANNOT ORDER PATIENT SUPPORT SERVICES

• Adempas REMS Patient Enrollment and Consent Form *Female patients only*

Be sure to include a copy of the patient's insurance card. Both the front and back of the card are required with the completed enrollment forms.

Adempas Prescription and Patient Support Program Enrollment Form *THE PATIENT SUPPORT ENROLLMENT SECTION IS FOR PATIENTS ONLY*

Section 4 – FOR PATIENTS ONLY

Optional Patient Support Program Enrollment for patients

- Inform patients of the option to enroll in the Aim Patient Support Program, which includes: follow-up nurse interactions, financial assistance, and educational information
- If the patient chooses to enroll in the support program, the patient must check the boxes for the services they choose to register for and initial to confirm their elections
- If patients elect educational information, patients must write their initials. This program is optional for patients.

REMS Program prior to initiating treatm	ent. Please visit Consent Form,	<u>us.com</u> . Prescribers and all female patients must <u>www.AdempasREMS.com</u> to access the Adempas and fax them along with patient insurance informa <u>dempasREMS.com</u> .	REMS materials including the		
SECTION 🕘 Patient S	upport P	rogram Enrollment			
Patient Support Program Enrollment					
benefit verification for Adempas and financial Adempas therapy ("myAIM"). These Programs	assistance for eligitate entirely optional	clude: (A) nurses to support you in starting therapy and ac ole patients and (C) education about CTEPH and/or PAH - and you may enroll in one or all of these Programs. To enro y to share your protected healthcare information with Bayer	as well as helpful tips for managing you Il in myAIM, you will need to sign a HIPA		
You will remain enrolled in each Program that you select unless you opt-out either by contacting myAIM via telephone at 1-855-423-3672 or by written notification sent to: 200 Pinecrest Plaza, Morgantown WV 26505, or until your HIPAAAuthorization expires.					
Please enroll me in: (check all that apply)	A: Nursing	B: Benefits Verification and Financial Assistance	C: Educational Information		
Patient – please initial here to confirm your optional elections:					
		ntacting the AIM program.			

HIPAA Authorization

Written Permission to Share Protected Health Information All patients (male or female) must sign and date if they choose to receive any Bayer services or communications.

Patients may choose to elect. This is optional for patients.






For female patients only

For all female patients, Adempas is only available through a restricted program under the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program. All female patients must be enrolled in the Adempas REMS program, and the Adempas REMS Patient Enrollment Form must be completed in addition to the Prescription and Patient Support Program Enrollment Form. For REMS enrollment, patient and prescriber signatures will be required on both forms.

Adempas REMS Patient Enrollment and Consent Form



including Boxed Warning, throughout, and <u>click here</u> for full Prescribing Information.

0.5mg 1mg 1.5mg 2mg 2.5mg

Common prior authorization criteria

Does your patient meet the prior authorization criteria?

- Consider the commonly required clinical criteria for PAH and CTEPH
- Utilizing a right heart catheterization (RHC), the following hemodynamic parameters can be obtained:

For both CTEPH and PAH

- Mean pulmonary arterial pressure (mPAP)
- Pretreatment pulmonary capillary wedge pressure (PAWP or PCWP)
- Pulmonary vascular resistance (PVR)

For CTEPH (WHO Group 4)

- CTEPH was confirmed by RHC
- Include documentation of ventilation/perfusion (V/Q) scan
- Medical reason(s) why a test could not be performed, if applicable

For PAH (WHO Group 1)

- PAH was confirmed by RHC
- Medical reason(s) why a test could not be performed, if applicable

The following are items frequently required on a PA for Adempas:

- Documented diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) or chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4), which may include pertinent patient medical history
- Diagnostic testing and relevant documentation often required:
 - RHC, including documented administration of vasoreactivity test
 - V/Q scan (for CTEPH patients)
 - Medical reason(s) why a test could not be performed, if applicable
 - Include Functional Class
 - Indicate previous treatments that have been tried and provide an explanation when applicable
- Please request approval for the initial dose and each strength for the titration schedule
- For quicker review, indicate on the form or check the box for expedited/urgent review
- It may be possible to request a multi-year authorization or a "lifetime" authorization

Key points to consider:

- Provide information from the indication section of the Adempas Prescribing Information for patients studied in clinical trials
- Please consult the payer policy for Adempas coverage to ensure the requirements have been addressed

If your PA or appeal is denied, please contact your Adempas Access and Coverage Manager (ACM) for additional support

For additional support with prior authorization and appeals, contact Aim Support 1-855-4ADEMPAS (1-855-423-3672)

Adempas is contraindicated in:

- Pregnancy. Based on data from animal reproduction studies, Adempas may cause fetal harm when administered to a pregnant woman and is contraindicated in females who are pregnant. Adempas was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
- Co-administration with nitrates or nitric oxide donors (such as amyl nitrite) in any form.
- Concomitant administration with specific phosphodiesterase (PDE)-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline) is contraindicated. Do not administer within 24 hours of sildenafil. Do not administer 24 hours before or within 48 hours after tadalafil.
- Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
- Patients with Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias (PH-IIP).

Please see additional Important Safety Information, including Boxed Warning, throughout, and click here for full Prescribing Information.



Support Program

Aim Patient

Prior authorization (PA) and appeals process cont.

Adempas Enrollment Form

Aim Patient Support Program

Addressing reasons for denial of prior authorization

- Refer to the denial letter for the specific reasons and directly address the payer* using the guidance below; there may be more than one issue requiring response, and thorough appeals are generally more successful
- Contact the payer for more information if a clear reason for refusal has not been provided

Example: If the denial states "does not meet medical criteria," request the reason, and ask for the specific criteria and data required. It may be possible to obtain that information in writing from the payer.

There are two options for handling the prior authorization appeals process with a payer:

1. Submit a written appeal letter

- An expedited written review is often also available. A result is generally provided within 24–72 hours, depending on the payer
- However, some payers may consider "expedited" to be 2 weeks or more

2. Request a verbal discussion

- Ask to speak directly to a clinical reviewer
- The prescribing physician can also request a peer-to-peer discussion with a cardiologist or pulmonologist to review the appeal
- Verbal discussions may provide the most rapid review of the case and allow the opportunity for back-and-forth discussion

If the PA or appeal is denied, you can contact your Adempas Access and Coverage Manager (ACM) for additional support

*Payer refers to any of the following: commercial health plan, Medicare, Medicaid, or any entity paying for prescription drugs.

WARNINGS AND PRECAUTIONS (continued)

Embryo-Fetal Toxicity. Based on data from animal reproduction studies, Adempas may cause embryo-fetal toxicity when administered to a pregnant female and is contraindicated in females who are pregnant. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment, monthly during treatment, and for one month after stopping treatment. Advise females of reproductive potential to use effective contraception during treatment with Adempas and for at least one month after the last dose.

For females, Adempas is only available through a restricted program under the Adempas REMS Program.

Please see additional Important Safety Information, including Boxed Warning, throughout, and <u>click here</u> for full Prescribing Information.



Access and Coverage Managers

An information resource for staff

Access and Coverage Manager (ACM)

Your resource to help navigate the enrollment and approval process for your Adempas patients

The ACM can:

- Provide patient and REMS enrollment support
- **Engage with you, your office,** the Aim Support Center, and your Adempas Sales Consultants
- Provide assistance with access and coverage issue resolution
- Offer expertise within managed care policies on the local, state, and national levels



Adempas Sampling Program and Hospital Program



Adempas Sampling Program

The Adempas Sampling Program will:

- Allow you to provide the starting dose of Adempas (either 0.5 mg or 1.0 mg) to new patients at no cost
- Provide samples in a convenient 90 count (30-day supply) to ensure your patients have enough product available to titrate*

Patients enrolled in the Adempas Sampling Program also have the option to receive support from the Aim Patient Support Program, including:

- Evaluation of insurance coverage and help in securing financial assistance
- Nursing support and patient education materials
- A patient education and counseling call with a pharmacist

Required forms

Patient Enrollment and Adempas REMS Program Enrollment are required to participate in the Adempas Sampling Program:

- Adempas Prescription and Patient Support Program Enrollment Form (all patients)
- Adempas REMS Patient Enrollment and Consent Form (female patients only)

Fax all completed forms to the Aim Coordination Center: 1-855-662-5200

Contact your representative to receive samples

*During this time, the Aim Support Program will assist in determining drug coverage for future prescriptions. In the event that more time is required for coverage determination, Bayer will provide product supply for up to 60 days.



Adempas Hospital Program

The Adempas Hospital Program can allow you to initiate Adempas in the hospital and continue treatment without interruption upon discharae.

- Check with your hospital pharmacy to ensure they are REMS certified and can dispense Adempas
- Prescriber completes and submits enrollment forms to include confirmation of starting dose and date and potential discharge date. Also, check the "Yes" box for "Is patient starting in hospital setting?"
- Prescriber completes the Adempas Hospital Program Checklist and faxes to the Aim Support Center with the patient enrollment forms
- Aim processes the enrollment and triages as a priority to the specialty pharmacy
- Adempas is shipped to the patient's home or prescriber's office within 72 hours of completed enrollment or upon hospital discharge
- Complimentary supply (up to 90 days) provided while working through approval process regardless of insurance coverage or lack of coverage

National Drug Code (NDC)

For a 3-day supply of Adempas (bottle of 9 tablets):

- 0.5 mg NDC 50419-250-91
- 2 mg NDC 50419-253-91 • 2.5 mg NDC 50419-254-91
- 1 mg NDC 50419-251-91 • 1.5 mg NDC 50419-252-91

Ordering through CuraScript

For hospital distribution only, Adempas is distributed exclusively through CuraScript Specialty Distribution

Phone: 1-877-599-7748

Fax: 1-800-862-6208

Support Program **Aim Patient**

WARNINGS AND PRECAUTIONS (continued)

Adempas REMS Program. Females can only receive Adempas through the Adempas REMS Program, a restricted distribution program. Important requirements of the Adempas REMS Program include the following:

- Prescribers must be certified with the program by enrolling and completing training.
- All females, regardless of reproductive potential, must enroll in the Adempas REMS Program prior to initiating Adempas. Male patients are not enrolled in the Adempas REMS Program.
- Female patients of reproductive potential must comply with the pregnancy testing and contraception requirements.
- Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive Adempas.

Further information, including a list of certified pharmacies, is available at www.AdempasREMS.com or 1-855-4ADEMPAS.

Please see additional Important Safety Information, including Boxed Warning, throughout, and click here for full Prescribing Information.



Adempas Enrollment Form

REMS Enrollment Form

Adempas Aim Patient Support Program

Aim Patient Support helps patients get access to Adempas

- Ensures completed enrollment forms
- Confirms prescriber is REMS certified
- Provides benefits verification
- Sends Prior Authorization (PA) form to prescriber's office
- Refers patients for assistance programs as needed
- Triages enrollment to specialty pharmacy







Access and **Financial Support**

Aim Nursing Support

myAim Education & Encouragement

2 easy ways for your patients to enroll in the Aim Patient Support Program

PHYSICIANS CANNOT ORDER PATIENT SUPPORT SERVICES

Patients can complete the Patient Support section of the Prescription Enrollment Form

Patients can call the Aim Support Center at 1-855-4ADEMPAS (1-855-423-3672)

Aim Access and Financial Support

Private Insurance/Commercial

Co-pay Assistance Program*

• The Co-pay Assistance Program is for all patients insured through commercial pavers: regardless of income, patients will pay \$0 for Adempas

Quick Start Program (QSP)⁺

Who is eligible?



• Only available to patients with commercial plans with no step edits

How does the QSP work?

 Once benefit investigation is completed, referral is triaged to the respective specialty pharmacy for dispensing

When are benefits processed? When will therapy be available?

- Benefits are not processed until coverage is secured
- No-cost supply (up to 90 days) will be dispensed

What happens when coverage is secured?

• Once coverage is secured, referral moves to commercial coverage without disruption of therapy

How do patients get started in the QSP?

• Patients are automatically enrolled if they have commercial insurance plans

*Patients must have private commercial insurance with a percentage coinsurance or co-pay requirement. Medicare or Medicaid patients are ineligible for the \$0 co-pay program. Assistance is for one year, after which patients must re-apply. Patients must notify the program of any change in their insurance status. Patients in certain states may be ineligible.

Government and Uninsured/Underinsured

• Patient Assistance Program^{*}: Patients who are unable to afford their medication may be eligible to receive Adempas at no cost for one year from the date of acceptance

 Independent Foundation Assistance: Patients requiring additional financial assistance for out-of-pocket costs will be referred to independent charitable organizations

All Patients

• Adempas Hospital Program[§]:

Patients who initiate treatment in the hospital can continue Adempas at no cost without interruption upon discharge while awaiting insurance confirmation. Patients may receive treatment up to 90 days while awaiting insurance approval. See page 6 for full details

Interim Assistance:

Patients receive Adempas at no cost when immediate insurance coverage cannot be secured or there are gaps in coverage

⁺For plans with no step edits. *Medicare Part D patients will be enrolled based on calendar year. [§]Some restrictions may apply.

WARNINGS AND PRECAUTIONS (continued)

Hypotension. Adempas reduces blood pressure. Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors. Consider a dose reduction if patient develops signs or symptoms of hypotension.

Bleeding. In the placebo-controlled clinical trials, serious bleeding occurred in 2.4% of patients taking Adempas compared to 0% of placebo patients. Serious hemoptysis occurred in 5 (1%) patients taking Adempas compared to 0 placebo patients, including one event with fatal outcome. Serious hemorrhagic events also included 2 patients with vaginal hemorrhage, 2 with catheter-site hemorrhage, and 1 each with subdural hematoma, hematemesis, and intra-abdominal hemorrhage.

Pulmonary Veno-Occlusive Disease. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Therefore, administration of Adempas to such patients is not recommended. Should signs of pulmonary edema occur, the possibility of associated PVOD should be considered and if confirmed, discontinue treatment with Adempas.

Please see additional Important Safety Information, including Boxed Warning, throughout, and click here for full Prescribing Information.

REMS Enrollment Form

PA and Appeals

Process



Nursing support and patient education



Aim Nursing Support

You can expect:

- Adempas information for patients and caregivers
- Explanation of titration
- Review of your patient's status for titration of doses
- Follow-up with the prescriber
- Explanation and review of your patient's schedule of nurse contacts (if requested by the patient)
- 24/7 hotline for your patients

Accredo and Caremark are the pharmacies that make up the Adempas Aim Nursing Support.

For important risk and use information, please click here for full Prescribing Information, including Boxed Warning.

PHYSICIANS CANNOT REOUEST NURSING SERVICES FOR PATIENTS



The most common adverse reactions occurring more frequently (≥3%) on Adempas than placebo were headache (27% vs 18%), dyspepsia/gastritis (21% vs 8%), dizziness (20% vs 13%), nausea (14% vs 11%), diarrhea

Other events that were seen more frequently in Adempas compared to placebo and potentially related to treatment were palpitations, nasal congestion, epistaxis, dysphagia, abdominal distension, and peripheral edema.

(12% vs 8%), hypotension (10% vs 4%), vomiting (10% vs 7%), anemia (7% vs 2%), gastroesophageal reflux disease (5% vs 2%), and constipation (5% vs 1%).

myAim Education & Encouragement

Information for your patient's treatment journey

- Educational support through key stages of treatment and what to expect along the way
- Personalized communications for patients and caregivers throughout treatment
- Tips for patients on what to talk with their doctors about
- Information about other online resources and support

Patients must complete and sign the Patient Support section of the Adempas Prescription and Patient Support Program Enrollment Form to opt in to myAim Education & Encouragement

BAYER, the Bayer Cross, and Adempas are registered trademarks of Bayer.

MOST COMMON ADVERSE REACTIONS



100 Bayer Boulevard, Whippany, NJ 07981 USA ©2021 Bayer PP-ADE-US-2374-1 October 2021

iOCiQUAt tablets